496 related articles for article (PubMed ID: 28849951)
1. Second-line treatments of small-cell lung cancers.
Baize N; Monnet I; Greillier L; Quere G; Kerjouan M; Janicot H; Vergnenegre A; Auliac JB; Chouaid C
Expert Rev Anticancer Ther; 2017 Nov; 17(11):1033-1043. PubMed ID: 28849951
[TBL] [Abstract][Full Text] [Related]
2. Current and future therapeutic approaches for the treatment of small cell lung cancer.
Rossi A; Tay R; Chiramel J; Prelaj A; Califano R
Expert Rev Anticancer Ther; 2018 May; 18(5):473-486. PubMed ID: 29544351
[TBL] [Abstract][Full Text] [Related]
3. Novel targeted strategies to overcome resistance in small-cell lung cancer: focus on PARP inhibitors and rovalpituzumab tesirine.
Van Den Borg R; Leonetti A; Tiseo M; Giovannetti E; Peters GJ
Expert Rev Anticancer Ther; 2019 Jun; 19(6):461-471. PubMed ID: 31148500
[No Abstract] [Full Text] [Related]
4. Optimal drugs for second-line treatment of patients with small-cell lung cancer.
Rossi A; Sacco PC; Sgambato A; Casaluce F; Santabarbara G; Palazzolo G; Maione P; Gridelli C
Expert Opin Pharmacother; 2016; 17(7):969-76. PubMed ID: 26878692
[TBL] [Abstract][Full Text] [Related]
5. Targeted Therapy and Immune Therapy for Small Cell Lung Cancer.
Gadgeel SM
Curr Treat Options Oncol; 2018 Sep; 19(11):53. PubMed ID: 30203184
[TBL] [Abstract][Full Text] [Related]
6. Unravelling the biology of SCLC: implications for therapy.
Sabari JK; Lok BH; Laird JH; Poirier JT; Rudin CM
Nat Rev Clin Oncol; 2017 Sep; 14(9):549-561. PubMed ID: 28534531
[TBL] [Abstract][Full Text] [Related]
7. Systemic Therapy of Extensive Stage Small Cell Lung Cancer in the Era of Immunotherapy.
Ragavan M; Das M
Curr Treat Options Oncol; 2020 Jun; 21(8):64. PubMed ID: 32601742
[TBL] [Abstract][Full Text] [Related]
8. Development of targeted therapy and immunotherapy for treatment of small cell lung cancer.
Saito M; Shiraishi K; Goto A; Suzuki H; Kohno T; Kono K
Jpn J Clin Oncol; 2018 Jul; 48(7):603-608. PubMed ID: 29762727
[TBL] [Abstract][Full Text] [Related]
9. Prospects of targeted and immune therapies in SCLC.
Hendriks LEL; Menis J; Reck M
Expert Rev Anticancer Ther; 2019 Feb; 19(2):151-167. PubMed ID: 30590971
[No Abstract] [Full Text] [Related]
10. Emerging drugs for small cell lung cancer: a focused review on immune checkpoint inhibitors.
Reddy HG; Qin A; Kalemkerian GP
Expert Opin Emerg Drugs; 2020 Sep; 25(3):353-366. PubMed ID: 32683991
[TBL] [Abstract][Full Text] [Related]
11. Medical treatment of small cell lung cancer: state of the art and new development.
Sgambato A; Casaluce F; Maione P; Rossi A; Sacco PC; Panzone F; Ciardiello F; Gridelli C
Expert Opin Pharmacother; 2013 Oct; 14(15):2019-31. PubMed ID: 23901936
[TBL] [Abstract][Full Text] [Related]
12. SCLC-State of the Art and What Does the Future Have in Store?
Kahnert K; Kauffmann-Guerrero D; Huber RM
Clin Lung Cancer; 2016 Sep; 17(5):325-333. PubMed ID: 27397481
[TBL] [Abstract][Full Text] [Related]
13. DLL3: an emerging target in small cell lung cancer.
Owen DH; Giffin MJ; Bailis JM; Smit MD; Carbone DP; He K
J Hematol Oncol; 2019 Jun; 12(1):61. PubMed ID: 31215500
[TBL] [Abstract][Full Text] [Related]
14. Personalized Therapy of Small Cell Lung Cancer.
Schneider BJ; Kalemkerian GP
Adv Exp Med Biol; 2016; 890():149-74. PubMed ID: 26703804
[TBL] [Abstract][Full Text] [Related]
15. Advances in pharmacotherapy of small cell lung cancer.
Kalemkerian GP
Expert Opin Pharmacother; 2014 Nov; 15(16):2385-96. PubMed ID: 25255939
[TBL] [Abstract][Full Text] [Related]
16. Challenging the recalcitrant disease-developing molecularly driven treatments for small cell lung cancer.
Mak DWS; Li S; Minchom A
Eur J Cancer; 2019 Sep; 119():132-150. PubMed ID: 31445197
[TBL] [Abstract][Full Text] [Related]
17. Rationale for chemotherapy, immunotherapy, and checkpoint blockade in SCLC: beyond traditional treatment approaches.
Spigel DR; Socinski MA
J Thorac Oncol; 2013 May; 8(5):587-98. PubMed ID: 23546044
[TBL] [Abstract][Full Text] [Related]
18. Development of molecularly targeted agents and immunotherapies in small cell lung cancer.
Sharp A; Bhosle J; Abdelraouf F; Popat S; O'Brien M; Yap TA
Eur J Cancer; 2016 Jun; 60():26-39. PubMed ID: 27060747
[TBL] [Abstract][Full Text] [Related]
19. [Molecular targeted therapies in small-cell lung cancer].
Levy A; Malouf GG; Besse B; Massard C; Soria JC
Bull Cancer; 2010 May; 97(5):535-45. PubMed ID: 20093224
[TBL] [Abstract][Full Text] [Related]
20. Role of Immune Checkpoint Inhibitors in Small Cell Lung Cancer.
Cooper MR; Alrajhi AM; Durand CR
Am J Ther; 2018; 25(3):e349-e356. PubMed ID: 29722737
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
